by Chhavi Madaan | 2020-07-30

The novel virus has led to every biotech and pharmaceutical company busy to develop a successful COVID-19 vaccine. Below are the names of the firms that are working for the same: –

Oxford-Astra Zeneca Vaccine

The pharmaceutical company Astra Zeneca in collaboration with the Serum Institute of India (SII) has planned to produce 1 billion doses of the vaccine at affordable prices in India and in low to middle-income countries. The vaccine named AZD1222 has been made from chimpanzee adenovirus known as ChAdOx1 and is currently undergoing a combined Phase 2/3 trials in the UK, Brazil, South Africa, and will soon be tested in India. The results are drawn so far stated that the vaccine triggered an immune response in people aged 18- 55 years and also showed an increase in the levels of protective neutralizing antibodies and immune T-cells targeting the virus. Phase 3 human clinical trials are likely to take place in the month of August and be launched as early as November.

Moderna Vaccine

Morderna vaccine has been prepared by using mRNA-1273, a synthetic form of genetic material from the virus that was designed to nudge the immune system into attack mode. Phase 1 trial showed that the vaccine is safe and reflected an immune response in all 45 healthy participants. It urges to start with phase 3 by recruiting 30,000 volunteers and the cost proposed for the entire course is expected to range from Rs 3700-4500 in India and for others, it will be $50-60. It has an agreement with the US government to produce 100 million doses and has also signed an agreement with Spain’s Laboratories Pharmaceutics Rovi SA, Swiss contract drug maker Lonza Group AG and the Israel government.

Pfizer-BioNTech Vaccine

This firm has recently joined partnership with the biotech firm BioNTech to develop a vaccine named BNT162b2. As per the results of phase 1/2, the vaccine has been found to induce an immune response in 30,000 volunteers. Such volunteers were given 2 doses at the trial time to produce virus-neutralizing antibodies. Conduction of phase 2/3 is in process. Pfizer is hoping to release the approval of the vaccine by early as October and will release it in the market by the end of the year. The cost for the same will vary from country to country.

Russian Vaccine

According to the report Bloomberg, Russia has planned to register the vaccine by August 10-12. The vaccine is said to be developed by Moscow’s Gamaleya Research Institute of Epidemiology and Microbiology. Phase 1 of this vaccine has already achieved the aim of assessing the safety of vaccines on humans and phase 2 has been started from 13 July to check the ability of the vaccine to trigger an immune response. Scientists and medical experts want that the vaccine to be released once all the required tests including safety and efficacy tests are carried out. Thus, Russia is likely to conduct phase 3 with volunteers thousands in numbers.


Leave a Reply

Your email address will not be published. Required fields are marked *